In vitro and in vivo considerations associated with parenteral sustained release products: a review based upon information presented and points expressed at the 2007 Controlled Release Society Annual Meeting.
Martinez
Marilyn
M
US Food and Drug Administration, Center for Veterinary Medicine, Office of New Animal Drug Evaluation, Rockville, Maryland 20855, USA. marilyn.martinez@fda.hhs.gov
Rathbone
Michael
M
Burgess
Diane
D
Huynh
Mai
M
D000818:Animals; D002626:Chemistry, Pharmaceutical; D003692:Delayed-Action Preparations; D004339:Drug Compounding; D004343:Drug Implants; D005079:Excipients / Q000737:chemistry; D006801:Humans; D007263:Infusions, Parenteral; D007700:Kinetics; D008081:Liposomes; D008863:Microspheres; D008954:Models, Biological; D008956:Models, Chemical; D019999:Pharmaceutical Solutions / Q000737:chemistry; D012995:Solubility; D013678:Technology, Pharmaceutical / Q000379:methods*; D019155:Veterinary Drugs / Q000008:administration & dosage / Q000009:adverse effects / Q000737:chemistry / Q000493:pharmacokinetics
D003692:Delayed-Action Preparations; D004343:Drug Implants; D005079:Excipients; D008081:Liposomes; D019999:Pharmaceutical Solutions; D019155:Veterinary Drugs